Refametinib
Cat. No.：YN350149
CAS No. ：923032-37-5
| 产品名称: | Refametinib |
| CAS No.: | 923032-37-5 |
| Chemical Name: | N-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]-cyclopropanesulfonamide |
| Synonyms: | BAY 869766; RDEA119 |
| 分子量: | 572.34 |
| 分子式: | C₁₉H₂₀F₃IN₂O₅S |
| SMILES: | O=S(C1(C[C@H](O)CO)CC1)(NC(C(NC(C(F)=C2)=CC=C2I)=C3F)=C(OC)C=C3F)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Refametinib (BAY 869766; RDEA119) 是一种口服有效，非ATP竞争的，选择性MEK1/MEK2变构抑制剂，IC50分别为 19 nM 和 47 nM。 |
| IC50和靶点: | [{name:"MEK1:19 nM (IC50)"},{name: "MEK2:47 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Iverson, C., Larson, G., Lai, C., et al.RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancerCancer Res.69(17),6839-6847(2009)
Diep, C.H., Munoz, R.M., Choudhary, A., et al.Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cellsClin. Cancer Res.17(9),2744-2756(2011)
Schmieder, R., Puehler, F., Neuhaus, R., et al.Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinomaNeoplasia15(10),1161-1171(2013)
Akinleye, A., Furgan, M., Mukhi, N., et al.MEK and the inhibitors: From bench to bedsideJ. Hematol. Oncol.6,27(2013)
